Pitt receives $2.8 million to train HIV/AIDS researchers in Mozambique, Brazil and India

April 17, 2009

PITTSBURGH, April 17 - The University of Pittsburgh has received a five-year, $2.8 million grant from the National Institutes of Health's Fogarty International Center to train researchers in regions of the world most hard-hit by the HIV/AIDS epidemic. The grant, part of the center's AIDS International Training and Research Program (AITRP), will allow Pitt to develop a training site in Mozambique, where there are an estimated 750 new HIV infections every day, and to expand programs underway in Brazil and India.

"The HIV/AIDS epidemic remains uncontrolled in many regions in the world," said principal investigator Lee Harrison, M.D., professor of medicine and epidemiology, University of Pittsburgh. "With an ever-growing number of patients in treatment programs, there is an urgent need for well-trained scientists to monitor patients and find out why people develop resistance to anti-HIV drugs." He said the Fogarty grant will give international researchers the tools and skills needed to do this vital work.

"America has become the leader in advancing prevention and treatment of HIV/AIDS in developing countries," said Roger I. Glass, M.D., Ph.D., director of the Fogarty International Center. "Training local researchers benefits their own countries and helps U.S. scientists develop new understanding and methods for combating disease."

The Pitt training program in Mozambique is based on a partnership forged in 2006 with Catholic University Mozambique, the site of one of only two medical schools in the southeastern African country. With 1.8 million people living with HIV and one physician for every 33,000 residents, Mozambique has very limited capabilities for research and few trained investigators, Dr. Harrison said. The growing epidemic disproportionately impacts women, many of them of childbearing age. In the region of Beira, where Catholic University is based, 34 percent of pregnant women are HIV-infected.

In Mozambique, the Pitt team will focus on training researchers in epidemiological methods to better understand the failure of antiretroviral treatment and answer basic questions about HIV prevalence. In Brazil, ranked second in number of reported AIDS cases in the Americas, training will focus on treatment and vaccine trials, tuberculosis research related to AIDS and the effectiveness of antiretroviral therapy in public clinics. In India, where there are 2.5 million HIV-infected people, training will center on laboratory studies on the molecular mechanisms of HIV and the development of anti-HIV vaccines using Indian strains.

The University of Pittsburgh received one of seven AITRP grants recently awarded. The AITRP has trained nearly 2,000 researchers overseas, most of whom remain in their countries to continue HIV/AIDS research, train young scientists and provide leadership to their governments on health issues. Co-directing the program with Dr. Harrison is Phalguni Gupta, Ph.D., professor in the Department of Infectious Diseases and Microbiology at the University of Pittsburgh Graduate School of Public Health.
-end-


University of Pittsburgh Schools of the Health Sciences

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.